Chagas disease: Antitrypanosomal drug therapy
- Caryn Bern, MD, MPH
Caryn Bern, MD, MPH
- Professor, Global Health Sciences
- University of California, San Francisco
Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi. Issues related to antitrypanosomal drugs will be reviewed here.
The approach to management of Chagas disease varies by phase and form of disease and is discussed in detail separately. (See "Chagas disease: Acute and congenital Trypanosoma cruzi infection" and "Chagas disease: Chronic Trypanosoma cruzi infection".)
The only drugs with proven efficacy against Chagas disease in human trials are benznidazole and nifurtimox [1,2]. In general, benznidazole is better tolerated and so is favored by most experts as the first-line treatment for Chagas disease . In addition, compared with nifurtimox, there are more recent clinical trial data for the use of benznidazole, which was used in both pediatric trials in the 1990s [4,5] and in the comparator arm of several new drug trials [6,7]. However, some patients tolerate nifurtimox better than benznidazole; when treatment with one drug must be discontinued, the other can be used as an alternative. Limited human data, supported by findings in animal models, suggest that T. cruzi strains may vary in their drug susceptibility [8-11].
Both benznidazole and nifurtimox are contraindicated in pregnancy, so effective contraception should be assured. In addition, both drugs demonstrate in vitro mutagenicity and have been associated with increased risk of lymphomas in experimental animals [12-15]. No increase in incidence of lymphoma has been observed among immunocompetent humans, although no long-term studies examining this issue have been conducted . An increased incidence of neoplasm was reported in a small series of heart transplantation recipients for Chagas disease .
Antitrypanosomal agents are contraindicated in patients with severe renal or hepatic dysfunction.
- Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97:3.
- Lopez-Velez R, Norman FF, Bern C. American Trypanosomiasis (Chagas Disease). In: Hunter's Tropical Medicine and Emerging Infectious Desease, 9th ed, Magill AJ, Ryan ET, Solomon T, Hill DR (Eds), Saunders, Philadelphia 2013. p.725.
- Bern C. Chagas' Disease. N Engl J Med 2015; 373:456.
- de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407.
- Sosa Estani S, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998; 59:526.
- Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014; 370:1899.
- Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. J Am Coll Cardiol 2017; 69:939.
- Boainain E. Tratamento etiologico da doença de Chagas na fase cro. Rev Goiania Med 1979; 25:1.
- Camandaroba EL, Reis EA, Gonçalves MS, et al. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop 2003; 36:201.
- Veloso VM, Carneiro CM, Toledo MJ, et al. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz 2001; 96:1005.
- Zingales B, Miles MA, Moraes CB, et al. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz 2014; 109:828.
- Ferreira RC, Ferreira LC. Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Braz J Med Biol Res 1986; 19:19.
- Gorla NB, Ledesma OS, Barbieri GP, Larripa IB. Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutat Res 1989; 224:263.
- Teixeira AR, Córdoba JC, Souto Maior I, Solórzano E. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Am J Trop Med Hyg 1990; 43:146.
- Teixeira AR, Silva R, Cunha Neto E, et al. Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes. J Comp Pathol 1990; 103:37.
- Kirchhoff LV. Chagas disease. American trypanosomiasis. Infect Dis Clin North Am 1993; 7:487.
- Bocchi EA, Higuchi ML, Vieira ML, et al. Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease. J Heart Lung Transplant 1998; 17:399.
- Drugs for Neglected Diseases Initiative. Press releases: U.S. FDA approves Chemo Group’s benznidazole to treat children with Chagas disease. https://www.dndi.org/2017/media-centre/press-releases/fda-approves-benznidazole-chagas-children/ (Accessed on September 06, 2017).
- Centers for Disease Control and Prevention. Chagas disease: Antiparasitic treatment. https://www.cdc.gov/parasites/chagas/health_professionals/tx.html (Accessed on September 06, 2017).
- Altcheh J, Moscatelli G, Mastrantonio G, et al. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis 2014; 8:e2907.
- Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364:2527.
- Pinazo MJ, Muñoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 2010; 54:4896.
- Salvador F, Sánchez-Montalvá A, Martínez-Gallo M, et al. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. Clin Infect Dis 2015; 61:1688.
- Tornheim JA, Lozano Beltran DF, Gilman RH, et al. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia. PLoS Negl Trop Dis 2013; 7:e2407.
- US Pharmacopeial Convention. Benznidazole, Convention UP (Ed), US Pharmacopeia Monographs, 1995.
- Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Arzneimittelforschung 1972; 22:1635.
- Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972; 22:1624.
- Forsyth CJ, Hernandez S, Olmedo W, et al. Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States. Clin Infect Dis 2016; 63:1056.
- Jackson Y, Alirol E, Getaz L, et al. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis 2010; 51:e69.
- US Pharmacopeial Convention. Nifurtimox, Convention UP (Ed), US Pharmacopeia Monographs, 1995.
- Ribeiro I, Sevcsik AM, Alves F, et al. New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis 2009; 3:e484.
- Diniz Lde F, Caldas IS, Guedes PM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010; 54:2979.
- Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115:55.
- Urbina JA. New advances in the management of a long-neglected disease. Clin Infect Dis 2009; 49:1685.
- Bahia MT, Diniz Lde F, Mosqueira VC. Therapeutical approaches under investigation for treatment of Chagas disease. Expert Opin Investig Drugs 2014; 23:1225.